Transdermal Delivery

Overview

Transdermal delivery is the administration of a substance through the skin with the intent of achieving systemic absorption and blood concentrations sufficient to produce effects at distant target sites. This distinguishes it from topical application, which aims for local effects at or near the application site.

Transdermal delivery systems (commonly patches) have been successful for small, lipophilic drug molecules such as nicotine, fentanyl, estradiol, and scopolamine. However, peptides present a formidable challenge for transdermal delivery because the skin's barrier function — particularly the stratum corneum — is highly effective at excluding hydrophilic macromolecules. As a result, unassisted transdermal delivery of peptides is generally not feasible, and active enhancement technologies are required to achieve meaningful systemic absorption.

When to Use

Transdermal delivery is relevant when:

• A non-invasive, needle-free route for systemic peptide delivery is desired
• An active enhancement technology (microneedles, iontophoresis, sonophoresis) is available for the specific peptide
• Sustained, controlled-release delivery over hours to days is the therapeutic goal
• The research protocol specifically evaluates transdermal peptide formulations
• Patient compliance with injection regimens is a significant barrier

Currently, no peptides are available as FDA-approved transdermal products. Transdermal peptide delivery remains primarily in the research and development phase.

Technique/Process

The Transdermal Barrier

The same barrier described for topical application applies to transdermal delivery, but the challenge is greater because the peptide must not only penetrate the epidermis but must cross into the dermal vasculature in sufficient quantities for systemic absorption:

• Stratum corneum — The rate-limiting barrier. Its lipid-rich, brick-and-mortar architecture excludes most molecules above approximately 500 Da. Most peptides are well above this threshold.
• Viable epidermis — Contains peptidases that can degrade peptides during transit.
• Dermis — Contains the capillary network where absorbed peptides enter the systemic circulation.

Passive Transdermal Delivery

For a molecule to permeate the skin passively, it ideally should be:

• Small (molecular weight below 500 Da)
• Moderately lipophilic (log P 1–3)
• Potent (effective at low systemic concentrations, since transdermal flux is limited)

Most peptides fail on all three criteria: they are too large, too hydrophilic, and require higher systemic concentrations than passive transdermal delivery can achieve.

Active Enhancement Technologies

Microneedle arrays — Devices containing hundreds of microscopic needles (typically 25–1000 micrometers in length) that painlessly pierce the stratum corneum without reaching nerve endings or blood vessels in the deeper dermis. Peptides can be:

• Coated onto solid microneedles and dissolve upon insertion
• Encapsulated in dissolving microneedle matrices
• Delivered through hollow microneedles connected to a reservoir
• Applied topically after microneedle pre-treatment creates transient microchannels

Microneedle delivery is the most actively investigated technology for transdermal peptide delivery and has shown promising results in preclinical and early clinical studies.

Iontophoresis — Uses a low-intensity electrical current (typically 0.1–0.5 mA/cm2) to drive charged peptide molecules across the skin by electromigration and electroosmosis. Most effective for small, charged peptides. Limited by skin irritation at higher current densities and by the molecular size of the peptide.

Sonophoresis — Uses low-frequency ultrasound (20–100 kHz) to transiently disrupt the lipid structure of the stratum corneum, creating pathways for peptide permeation. Can increase skin permeability by 10–1000 fold for short periods.

Thermal ablation — Brief application of heat creates micropores in the stratum corneum without damaging deeper tissue layers. The resulting channels allow peptide permeation for several hours before the skin barrier regenerates.

Chemical enhancers — Similar to those used in topical formulations, but applied more aggressively to achieve deeper penetration. Include fatty acids, surfactants, terpenes, and specialized solvents.

Transdermal Patches

For small-molecule drugs, transdermal patches provide controlled, sustained delivery:

• Matrix patches — The drug is dispersed within an adhesive polymer matrix. Release is controlled by diffusion through the matrix.
• Reservoir patches — The drug is contained in a liquid or gel reservoir separated from the skin by a rate-controlling membrane.

For peptides, these passive patch designs are generally insufficient. Combination approaches (e.g., microneedle patch with a peptide reservoir) represent the most promising path forward.

Advantages/Disadvantages

Advantages

• Non-invasive or minimally invasive (microneedles) — avoids needle anxiety
• Sustained, controlled delivery — can maintain relatively constant blood levels
• Avoids first-pass hepatic metabolism
• Avoids GI degradation (unlike oral administration)
• Potential for self-administration without injection training
• Can be removed to terminate delivery (for patch-based systems)
• Improved compliance compared to multiple daily injections

Disadvantages

• The skin barrier severely limits passive delivery of peptides — active enhancement is required
• Enhancement technologies are still largely in development for peptide applications
• Skin irritation is common with chemical enhancers, iontophoresis, and adhesive patches
• Bioavailability is typically lower and more variable than injection routes
• Peptide degradation can occur within the delivery device and during skin transit
• Limited dose capacity — transdermal delivery is generally suitable only for potent peptides effective at low doses
• Cost of enhancement devices (microneedle arrays, iontophoresis units) exceeds simple injection supplies
• Individual variability in skin permeability (age, hydration, site, skin condition) affects dose consistency

Safety

• Skin irritation and sensitization are the most common adverse effects of transdermal delivery systems, particularly those employing chemical enhancers or adhesives
• Microneedle arrays should be single-use and disposed of properly — reuse increases infection risk
• Iontophoresis can cause electrical burns at high current densities or prolonged application; follow device specifications precisely
• Peptide stability within the transdermal device must be verified — elevated skin temperature (32-35 degrees C) and moisture can accelerate degradation
• Do not apply transdermal systems to damaged, inflamed, or diseased skin, as barrier function is already compromised and absorption may be unpredictably increased
• Monitor application sites for persistent erythema, vesiculation, or allergic contact dermatitis
• Be aware that transdermal pharmacokinetic profiles differ from injection profiles — half-life, time to peak concentration, and total exposure (AUC) may all differ, requiring independent dose optimization

Related Topics

• Topical Application — Local skin delivery, distinct from systemic transdermal delivery
• Subcutaneous Injection — The standard parenteral route with established bioavailability
• Bioavailability — A central challenge for transdermal peptide delivery
• Half-Life — Sustained transdermal delivery can extend effective half-life
• Oral Peptide Administration — Another non-injection route with distinct absorption challenges